Clinical significance of alpha1-adrenoceptor selectivity in the management of benign prostatic hyperplasia.
Alpha1-adrenoceptor antagonists have been shown to provide effective relief from symptoms of benign prostatic hyperplasia (BPH) with attendant improvements in quality of life. Although the alpha1A-adrenoceptor subtype predominates over other subtypes of alpha1 adrenoceptors in the prostate gland, there is no evidence that a subselective alpha-adrenoceptor antagonist provides a clinical advantage over a selective alpha1-adrenoceptor antagonist in the treatment of patients with BPH. The pharmacokinetic profiles of alpha1A-adrenoceptor antagonists and their documented penetration of the blood-brain barrier (CNS adverse effects) preclude a clinical benefit of subselective alpha-adrenoceptor blockers over selective alpha1 blockers.
Pool
J L
JL
Department of Medicine, Baylor College of Medicine, Houston, TX 77030, USA. Jpool@bcm.tmc.edu
Kirby
R S
RS
D000317:Adrenergic alpha-Antagonists / Q000493:pharmacokinetics / Q000627:therapeutic use*; D000368:Aged; D000369:Aged, 80 and over; D001812:Blood-Brain Barrier; D017292:Doxazosin / Q000493:pharmacokinetics / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008875:Middle Aged; D011470:Prostatic Hyperplasia / Q000188:drug therapy*; D011799:Quinazolines / Q000493:pharmacokinetics / Q000627:therapeutic use*; D018340:Receptors, Adrenergic, alpha-1 / Q000145:classification* / Q000378:metabolism
D000317:Adrenergic alpha-Antagonists; D011799:Quinazolines; D018340:Receptors, Adrenergic, alpha-1; C047638:alfuzosin; D017292:Doxazosin